Synpromics has won the ‘best emerging UK synthetic biotech company’ at the annual OBN Awards, which celebrate innovation and achievement across the UK life sciences industry.
Award
The company was nominated for its progress in the field of gene control, enabling safer, more effective cell and gene medicines through proprietary genomics, bioinformatics and intelligent data-driven design.
“We could not be happier with the outcome of last night’s Awards,” commented Michael Roberts, founder & CSO of Synpromics, when receiving the award. “This accolade is testament to the significant progress we have made over the past year, in growing our business by expanding the number of partnerships that we have with top pharma and biotech companies and significantly expanding our team.”
The OBN Awards are now in their ninth year and include emerging to late-stage R&D companies as well as life science investors. The Awards cover Biotech, Medtech, Synthetic Biology and Digital Health.